HomeMost PopularInvesting Acadia's Nuplazid Sales Drive Growth Amid...

Acadia’s Nuplazid Sales Drive Growth Amid Competition Acadia’s Nuplazid Revolutionizes CNS Disorder Treatment

Actionable Trade Ideas

always free

Acadia Pharmaceuticals Inc. ACAD is a biopharmaceutical company centered on revolutionizing medicine to combat unmet medical needs in central nervous system (CNS) disorders.

Nuplazid (pimavanserin), Acadia’s flagship product, represents a breakthrough as the first and only FDA-approved treatment for hallucinations and delusions associated with Parkinson’s disease psychosis, marking its debut in May 2016. With robust uptake, Nuplazid sales have consistently surged year-over-year.

Expanding Portfolio and Revenue Boost

In March 2023, Acadia garnered FDA approval for its new drug, Daybue, aimed at treating Rett syndrome in adult and pediatric patients aged two years and older. Following a noteworthy first full quarter of commercialization, Daybue logged impressive net product sales of $66.9 million after its launch in April 2023. The incremental revenues from Daybue are poised to alleviate the dependence on Nuplazid sales.

The acquisition of rights to market trofinetide outside North America, along with exclusive global rights to Neuren’s development candidate, NNZ-2591, has further solidified Acadia’s position in the market.

Over the past year, Acadia’s shares have surged 97.1%, significantly outperforming the industry’s 14.1% decline.

Zacks Investment Research

Image Source: Zacks Investment Research

Positive Patent Rulings and Future Prospects

In a recent breakthrough, a U.S. District Court in Delaware issued two rulings favoring Acadia’s Nuplazid patent, preserving its potential for future sales growth. The absence of generic alternatives in the market is expected to bolster Nuplazid’s market position.

Acadia is evaluating the expansion of Nuplazid’s indications to schizophrenia-negative symptoms. If approved, this expansion is set to further elevate the drug’s sales.

Diversification Efforts and Competitive Landscape

In addition to its existing portfolio, Acadia has made strides in broadening its offerings beyond Nuplazid. The company has initiated a phase III COMPASS study evaluating the efficacy and safety of carbetocin nasal spray (ACP-101) for the treatment of hyperphagia in Prader-Willi syndrome (PWS).

Furthermore, the mid-stage study to evaluate the safety and efficacy of ACP-204 in the treatment of hallucinations and delusions associated with Alzheimer’s disease psychosis has also been launched.

The potential approvals of these drugs in the future will significantly reduce the company’s dependence on Nuplazid for revenue generation and expand its commercial portfolio.

However, despite these promising developments, Acadia’s sole reliance on Nuplazid for growth remains a concern. Though the company now markets Daybue for Rett Syndrome, its uptake will take time, leaving a heavy dependence on Nuplazid for now.

Acadia also faces fierce competition from other players in the market, notably Axsome Therapeutics, which poses a significant challenge to Acadia’s product lineup.

Zacks Rank and Stock Comparison

Acadia currently holds a Zacks Rank #3 (Hold). Notwithstanding, other drug/biotech stocks such as Puma Biotechnology, Inc. and ADMA Biologics have been performing notably well, providing compelling alternatives for investors seeking promising prospects.

While Puma Biotech sports a Zacks Rank #1 (Strong Buy), ADMA carries a Zacks Rank #2 (Buy). Both these options present investors with enticing potential.

As the pharmaceutical landscape continues to evolve, Acadia’s innovative approach and strategic initiatives position it well to navigate through the competitive terrain and further bolster its market standing.

Swing Trading Ideas and Market Commentary

Need some new swing ideas? Get free weekly swing ideas and market commentary from Jonathan Bernstein here: Swing Trading.

Explore More

Weekly In-Depth Market Analysis and Actionable Trade Ideas

Get institutional-level analysis and trade ideas to take your trading to the next level, sign up for free and become apart of the community.